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ATP citrate-lyase (ACL) is a key enzyme supplying
acetyl-CoA for fatty acid and cholesterol synthesis. Its
expression is drastically up-regulated when an animal is
fed a low fat, high carbohydrate diet after prolonged
fasting. In this report, we describe the role of sterol
regulatory element-binding proteins (SREBPs) in the
transactivation of the rat ACL promoter. ACL promoter
activity was markedly stimulated by the overexpression
of SREBP-1a and, to a lesser extent, by SREBP-2 in Al-
exander human hepatoma cells. The promoter elements
responsive to SREBPs were located within the 55-base
pair sequences from 2114 to 260. The gel mobility shift
assay revealed four SREBP-1a binding sites in this re-
gion. Of these four elements, the 2102/294 region, imme-
diately upstream of the inverted Y-box, and the 270/261
region, just adjacent to Sp1 binding site, played critical
roles in SREBPs-mediated stimulation. The mutation in
the inverted Y-box and the coexpression of dominant
negative nuclear factor-Y (NF-Y) significantly attenu-
ated the transactivation by SREBP-1a, suggesting that
NF-Y binding is a prerequisite for SREBPs to activate
the ACL promoter. However, the multiple Sp1 binding
sites did not affect the transactivation of the ACL pro-
moter by SREBPs. The binding affinity of SREBP-1a to
SREs of the ACL promoter also was much higher than
that of SREBP-2. The transactivation potencies of the
chimeric SREBPs, of which the activation domains (70
amino acids of the amino terminus) were derived from
the different species of their carboxyl-terminal region,
were similar to those of SREBPs corresponding to their
carboxyl termini. Therefore, it is suggested that the car-
boxyl-terminal portions of SREBPs containing DNA
binding domains are important in determining their
transactivation potencies to a certain promoter.
ATP citrate-lyase (ACL)1 is a cytosolic enzyme that catalyzes
the cleavage of citrate into oxaloacetate and acetyl-CoA (1). In
liver and adipose tissue, this enzyme plays an important role in
supplying acetyl-CoA for both fatty acid and cholesterol syn-
thesis (2). As the specific inhibition of ACL in rats significantly
decreases the plasma levels of triacylglycerol and cholesterol,
ACL is expected to be a potential target for hypolipidemic
intervention (3, 4). The activity of ACL is mainly regulated at
the level of transcription by diet regimen and insulin, like other
lipogenic enzymes, such as fatty acid synthase and acetyl-CoA
carboxylase (5). The sequences of the 59 flanking region of the
ACL gene are highly conserved in humans and rats, whereas
there is no homology in the regions of the 59 untranslated
region and the first intron, suggesting that transcription is
regulated in the same manner in these two species (6, 7).
Although ACL plays an important role in fatty acid and cho-
lesterol biosynthesis and is highly controlled by diet at the
transcription level, studies on the structure and function of this
promoter have been very limited thus far.
SREBPs are the transcription factors that regulate the tran-
scription of many genes involved in cholesterol and fatty acid
synthesis, such as low density lipoprotein (LDL) receptor, far-
nesyl-pyrophosphate synthase, squalene synthase, hydroxy-
methylglutary-CoA reductase, hydroxymethylglutary-CoA syn-
thase, fatty acid synthase, and acetyl-CoA carboxylase (8–12).
Nascent SREBPs reside in the endoplasmic reticulum and the
nuclear envelope as precursor forms (13). The transcriptionally
acitive amino-terminal segments are released from the precur-
sor SREBPs by a sequential two-step cleavage process. Once
cleaved, the amino-terminal segment translocates into the nu-
cleus where it binds to sterol regulatory elements (SREs) in the
promoters of target genes. Three isoforms of SREBPs have
been identified. SREBP-1a and -1c are derived from a single
gene, using different transcription start sites. SREBP-1c is
known as a weak activator because of its short acidic domain.
SREBP-2 is transcribed from a separate gene, and it shows
about 50% sequence homology to SREBP-1 isoforms. The in
vivo roles of the SREBP isoforms have been characterized in
transgenic mice overexpressing active forms of each isoform
(14–16). Those reports have shown that SREBP-1 is associated
more with the genes involved in fatty acid synthesis, whereas
SREBP-2 preferentially stimulates genes involved in choles-
terol synthesis. For example, transgenic mice that overexpress
the active forms of SREBP-1a and -1c showed more elevated
expression of the mRNAs of lipogenic enzymes such as fatty
acid synthase and acetyl-CoA carboxylase than those of the
LDL receptor and other cholesterogenic enzymes.
Recent reports have shown that SREBP-1 might be the po-
tential transactivator that mediates lipogenic enzyme gene
regulation during the fasting/refeeding cycle. Refeeding a high
carbohydrate/low fat diet following long-term fasting up-regu-
lates the nuclear concentration of mature SREBP-1 and its
mRNA in adipose tissue and liver (17, 18). Recently, insulin
was reported to increase SREBP-1c mRNA in streptozotocin-
induced diabetic rat liver and isolated hepatocytes, and
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SREBP-1c was suggested as possibly mediating insulin action
upon regulation of the genes involved in lipid and carbohydrate
metabolism (19, 20). However, the action of the SREBPs on the
promoters of lipogenic enzymes is confirmed in only a few
genes, which include fatty acid synthase, acetyl-CoA carboxyl-
ase, stearoyl-CoA desaturase, and glycerol-3-phosphate acyl-
transferase (21–25). Thus, studies on SREBP activation of
other lipogenic genes including ACL may add more data for the
generalization of the hypothesis.
In this study, we demonstrate that SREBPs stimulate the
ACL promoter through their binding to an upstream promoter
region and that the activation requires NF-Y binding. We also
show that SREBP-1a and -2 have different potencies in acti-
vating the ACL promoter derived from their carboxyl-terminal
domain and not from the amino-terminal activation domain.
MATERIALS AND METHODS
Cell Culture—Alexander cells obtained from ATCC were cultured in
minimal essential medium supplemented with 10% fetal calf serum,
100 unit/ml penicillin G-sodium, 100 mg/ml streptomycin sulfate, and
0.25 mg/ml amphotericin B. All cell culture materials were purchased
from Life Technologies, Inc.
Construction of ACL Promoter-Luciferase Plasmids—The rat ACL
promoter fragments spanning 21860 to 167, 2419 to 167, 299 to 167,
and 260 to 167 were amplified by polymerase chain reaction (PCR)
using Pfu polymerase and respective primers based on the sequences
reported previously (6). The amplified fragments were gel-purified with
a Qiaquick gel extraction kit (Qiagen Inc.) and then subcloned into the
SmaI site of pGL3-basic plasmid (Promega, Madison, WI). The ACL
promoter-luciferase constructs were designated as pACL1860,
pACL419, pACL99 and pACL60, respectively. Plasmid pACL114 con-
struct was generated by the deletion of the SacI fragment of 2419 to
2115 from pACL419. Mutant constructs were generated from pACL114
and pACL419 with the mutagenic oligonucleotides (20 mer) using the
QuikChangeTM site-directed mutagenesis kit (Stratagene). The mu-
tated sequences are shown in Figs. 3 and 4. The sequences of all the
constructs were confirmed using the T7 sequencing kit (Amersham
Pharmacia Biotech). The construct of p5xSRE-tk was generated by
inserting 5 copies of LDLR SRE1 sequence I into SacI site and herpes
simplex thymidine kinase promoter into SmaI and XhoI sites of pGL3-
basic plasmid. All transfection plasmids were prepared with the Qiagen
Plasmid Midi Kit (Qiagen Inc.).
Transient Transfection Assay—Alexander cells were plated at a den-
sity of 2 3 105 cells/35-mm dish. On the following day, transfection was
performed with 0.4 mg of the indicated ACL promoter-luciferase con-
structs, 0.2 mg of pCMV-b-galactosidase plasmid (CLONTECH), and
the indicated amounts of pcDNA3 (Invitrogen) or SREBP expression
plasmids pCSA10 or pCS2. Plasmid pCSA10, which encodes amino
acids 1–490 of SREBP-1a, and pCS2, which encodes amino acids 1–485
of SREBP-2, were provided by Dr. T. Osborne (University of California,
Irvine). The chimeric SREBPs constructs (Fig. 5) were generated as
follows: the BglII restriction site was introduced into pCSA10 and pCS2
at the 70th codon of SREBPs cDNA, and the EcoRI-BglII fragments
(220 base pairs) corresponding to activation domains were exchanged
between pCSA10 and pCS2. Plasmid pmYA (D4YA13 m29), which en-
codes the dominant negative form of the A subunit of NF-Y, was also
used in the indicated transfection experiment; it was provided by Dr. R.
Mantovani (University of Milan, Italy) (26). Transfection was per-
formed using FuGENE6 transfection reagent (Roche Molecular Bio-
chemicals) for 6 h according to the manufacturer’s instructions. After 2
days, cells were washed with phosphate-buffered saline (Life Technol-
ogies, Inc.) and lysed in 200 ml of reporter lysis buffer (Promega).
Luciferase activities were measured using the Luciferase Assay System
(Promega) and normalized with b-galactosidase activities (27) to correct
the transfection efficiency. Relative luciferase activity is expressed as
the normalized luciferase activity per microgram of protein.
Preparation of Recombinant Human SREBPs and Nuclear Ex-
tracts—Recombinant human SREBPs were expressed in Escherichia
coli BL21(DE3)pLysS. SREBP expression vectors pET-SREBP-1a and
pET-SREBP-2 were generated by inserting the cDNA fragments from
pCSA10 and pCSA2, respectively, between the EcoRI and SalI sites of
pET-21a (Novagen). The bacteria freshly transformed with each expres-
sion vector were grown to mid-log phase, and proteins were induced for
4 h with 1 mM isopropyl-b-D-thiogalactopyranoside. The bacteria were
harvested by centrifugation and disrupted by sonication. The recombi-
nant proteins containing amino-terminal T7 and carboxyl-terminal
polyhistidine (His6) tag were purified to homogeneity by Ni-NTA-aga-
rose (Qiagen) chromatography. The purity and concentration of the
recombinant proteins were verified by SDS-polyacrylamide gel elector-
phoresis followed by Coomassie Brilliant Blue staining. Nuclear ex-
tracts were prepared from the livers of Harlan Sprague-Dawley rats
(weighing about 200 g) according to the procedures described previously
by Gorski et al. (28).
DNase I Footprinting—The probes corresponding to nucleotides
2142 to 167 of the ACL promoter were generated by PCR using
pACL419 as a template. 32P-labeled sense oligonucleotides (nucleotides
2142 to 2116) and unlabeled antisense oligonucleotides (136 to 167)
were used to label the sense strand, whereas 32P-labeled antisense
oligonucleotides (220 to 15) and unlabeled sense oligonucleotides
(2142 to 2116) were used as primers to label the antisense strand. The
PAGE-purified probes (50,000 cpm) were incubated with 0, 1, 2, and 4
mg of purified SREBP-1a for 20 min on ice in 50 ml of reaction buffer
containing 10 mM HEPES, pH 7.9, 60 mM KCl, 1 mM EDTA, 5 mM
dithiothreitol, 7% glycerol, and 1 mg of poly(dI-dC). Then, DNase I
(Roche Molecular Biochemicals) diluted in 50 ml of 10 mM MgCl2, 5 mM
CaCl2 was added to the DNA-protein binding reactions. After a 2-min
incubation at room temperature, the digestion reactions were stopped
by adding 100 ml of stop buffer containing 1% (w/v) SDS, 200 mM NaCl,
20 mM EDTA, pH 8.0, and 0.1 mg/ml glycogen. The DNA was extracted
with phenol/chloroform and recovered by ethanol precipitation. The
pellets were dissolved in loading buffer and then resolved on denaturing
6% polyacrylamide gel. The footprints were compared with the G1A
ladder produced by the chemical cleavage sequencing reaction of the
same probe to determine the corresponding nucleotide sequences.
Gel Mobility Shift Assay—The probes corresponding to nucleotides
299 to 241 and 2142 to 280 of the ACL promoter were generated by
PCR using 32P-labeled primers (20 mer) and pACL419 plasmid as a
template. To generate mutant probes, corresponding mutant pACL419
plasmids were used as templates. The PAGE-purified probes (20,000
cpm) were incubated with purified recombinant SREBPs (1 mg) or liver
nuclear extract (7.5 mg) in a final volume of 20 ml containing 10 mM
HEPES, pH 7.9, 75 mM KCl, 1 mM EDTA, 5 mM dithiothreitol, 5 mM
MgCl2, 10% glycerol, 1 mg of poly(dI-dC), and 0.5% BSA. After a 20 min
incubation at room temperature, samples were resolved on a 4% poly-
acrylamide gel in 13 TBE (45 mM Tris, 45 mM boric acid, 1 mM EDTA)
at 200 V for approximately 1 h at 4 °C. For the competition assays,
unlabeled oligonucleotides indicated in the figures were added to the
reactions at an approximately 100-fold molar excess. For the NF-Y
supershift assay, the antibody against the B subunit of NF-Y (0.2 mg),
provided by Dr. R. Mantovani, was added to the reactions. The se-
quences (coding strands) of the oligonucletides used in the competition
assays are as follows: NF-Y, 59-GGGGTAGGAACCAATGAAATGAAA-
GGT-39 (29); LDL receptor-SRE1, 59-TTTGAAAATCACCCCACTGCA-
AAC-39 (9); ACL 2142/2116, 59-AGCAGCGAATGGGGAGGAGCCTA-
GAGC-39; ACL 2102/273, 59-GCGTGTGCCCAATCGCCAGGCTGCAT-
GGCC-39; ACL 267/241, 59-GCTGATGGGGGGCGGGGAGGAG-
CCCG-39.
RESULTS
SREBPs Strongly Induced ACL Promoter Activity—To deter-
mine whether SREBPs are able to activate the rat ACL pro-
moter and to focus on the responsive regions, we prepared a
series of plasmid constructs containing the various lengths of
the rat ACL promoter linked to the luciferase gene. ACL pro-
moter-reporter constructs and the putative binding sites of
transcription factors are shown in Fig. 1. The nucleotide se-
quence is numbered based on the published sequence of the rat
ACL gene (6). Promoter-reporter constructs were transiently
transfected into the Alexander cells in the presence or absence
of pCSA10 or pCS2 encoding the mature form of human
SREBP-1a or SREBP-2, respectively (Fig. 1). The luciferase
activity indicating ACL promoter activity was increased by the
overexpression of SREBP-1a and SREBP-2. In most constructs
tested, SREBP-1a showed higher activation than SREBP-2.
The level of promoter activities of pACL1860 and pACL419
were almost the same in presence or absence of SREBPs. Nu-
cleotide sequence analysis showed six Sp1 binding sites and
one NF-Y binding site in the region from 2419 to 167 (6).
Deletion of five Sp1 binding sites (pACL114) markedly de-


































creased the basal transcription to 16% relative to that of
pACL419. However, the luciferase activity of pACL114 could be
highly induced to the level of 98% and 58% of the induced
activity of pACL419 by SREBP-1a and 22, respectively.
Further deletion to nucleotide 2100 (pACL99) reduced the
enhancement by SREBP-1a and -2 to the level of 43 and 70%,
respectively, of the induced activity of pACL114. Deletion
to 261 (pACL60) abolished the basal transcription activity
and the transactivation of SREBPs. The constructs
pACL114D(299/280) and pACL114D(279/260), which were
generated from pACL114 by deleting the region from 299 to
280 and from 279 to 260, respectively, significantly decreased
the induction by SREBPs. These results demonstrated that the
SREs responsible for the induction of ACL promoter activity by
SREBPs exist in the region from 2114 to 260.
SREBP Binding Regions Were Determined by DNase I Foot-
printing and Gel Mobility Shift Assay—To localize the
SREBP-1a binding sites in the region from 2114 to 260 of the
ACL promoter, DNase I footprinting was performed using pu-
rified recombinant human SREBP-1a expressed in E. coli (Fig.
2). SREBP-1a protected two regions, from 272 to 257 and from
288 to 2113, adjacent to the inverted Y-box. The inverse
sequence of 271 to 262 (GTGAGCTGAT/ATCAGCTCAC) has
80% homology to SRE1 (ATCACCCCAC) identified in the pro-
moter of LDL receptor (8). The sequence from 2116 to 2107
(CTCAGGCTAG) has 90% homology to SRE3 (CTCAGCCTAG)
of glycerol-3-phosphate acyltransferase promoter (25).
To confirm the SREBP binding to these two footprinted re-
gions, gel retardation assays were done. We prepared down-
stream (299/241) and upstream probes (2142/280) covering
the protected regions (Figs. 3A and 4A). SREBP-1a produced
two shifted bands with 299/241 probe (Fig. 3B), of which the
upper band was the complex containing two molecules of
SREBP-1a. When the LDLR-SRE1 sequence was added to the
reaction as a competitor, both shifted bands disappeared com-
pletely. Although competitor 2102/273, containing inverted
Y-box, slightly decreased the complex formation, neither the
conserved NF-Y binding sequence reported nor the Sp1-binding
sequence, which exists in the ACL promoter (267/241), com-
peted complex formation. To determine the precise binding
sites for SREBP-1a, we introduced mutations in the probes
(Fig. 3A). The substitutions of three base pairs in the conserved
SRE1 region of 299/241 probe produced the mutant oligonu-
cleotides m1 and m2, which formed complexes with the
SREBP-1a at significantly lower but still detectable levels (Fig.
3C). The mutation of the inverted Y-box (CCAAT) to CGTTT
(m4) slightly decreased the formation of the complex and pre-
vented the formation of complex containing two molecules of
SREBP-1a (Fig. 3C). The mutations in both conserved SRE1
and inverted Y-box (m214) completely inhibited binding of
SREBP-1a to the probe (Fig. 3C). Because all probes were
generated by PCR using the same 32P-labeled antisense primer
(260/241) and then PAGE-purified, the differences in inten-
sity between shifted bands were not caused by the differences
in the specific activities between wild type and mutant probes.
These results suggest that SREBP-1a binds not only to the
conserved SRE1 sequence but also weakly to the inverted Y-box
in the ACL promoter.
When the 299/241 probe was incubated with nuclear ex-
tracts isolated from rat liver, one major shifted band was pres-
ent (Fig. 3D, lane 1). This band disappeared when anti-NF-YB
antibody was added to the reaction (Fig. 3D, lane 2), suggesting
that this band was produced by the binding of NF-Y. The NF-Y
band was not present if the mutated inverted Y-box (m4) was
used as a probe (Fig. 3D, lanes 5–8). When SREBP-1a was
added to the reaction, an additional shifted band with lower
FIG. 1. Transcriptional activation of the ACL promoter by the
overexpression of SREBPs. The ACL promoter-luciferase constructs
used in the experiments are shown on the left side of the graph. The
putative binding sites for Sp1 and NF-Y are indicated by ovals and
square, respectively. Triplicate dishes of Alexander cells were trans-
fected with 0.4 mg of the indicated ACL promoter-luciferase plasmids
and 0.2 mg of pCMV-b-galactosidase plasmid to normalize the transfec-
tion efficiency. In addition, SREBP expression plasmids pCSA10 (gray
bars), pCS2 (black bars) or negative control pcDNA3 (white bars) were
also added to 0.4 mg using FuGENE6 reagent. After a 2-day incubation
in medium supplemented with 10% fetal calf serum, luciferase activi-
ties and b-galactosidase activities were measured. The values indicate
normalized luciferase activity/mg of protein in the cell extracts and
represent the mean 6 S.E. obtained from three independent
experiments.
FIG. 2. Determination of the SREBP-1a binding sites in the
ACL promoter by DNase I footprinting. The 209-bp DNA fragments
of the ACL promoter (nucleotides 2142 to 167) were 32P-labeled at the
end of the sense or antisense strand and then PAGE-purified. The
radiolabeled probes and the purified human recombinant SREBP-1a
expressed in E. coli were used for the reaction. The preparation of
recombinant protein and DNase I footprinting assay was performed as
described under “Materials and Methods.” DNase I-treated reaction
mixtures were subjected to electrophoresis on denaturing 6% polyacryl-
amide gel. The same radiolabeled probes were also subjected to chem-
ical cleavage sequencing reactions (G 1 A). The reaction products in the
lanes are as follows: lanes 1 and 7, G 1 A reaction; lanes 2 and 6,
reactions without protein; lanes 3–5, reactions with 1, 2, and 4 mg of
SREBP-1a, respectively. The protected regions (boxes) and their rela-
tive positions in the ACL promoter are indicated.


































mobility, which was not clearly separated from the complex
containing two molecules of SREBP-1a, was produced as well
as the bands formed by NF-Y or SREBP-1a alone (Fig. 3D, lane
3). This additional band is produced presumably by the binding
of both NF-Y and SREBP-1a, because this complex was super-
shifted by the anti-NF-YB antibody (Fig. 3D, lane 4), and the
addition of SREBP-1a diminished the complex formed by NF-Y
alone.
The upstream probe, 2142280 (Fig. 4A), also produced the
three shifted bands with SREBP-1a (Fig. 4B). The binding of
SREBP-1a was completely competed by the conserved SRE1
sequence of the LDL receptor promoter but was not competed
by the conserved Y-box (29) or the oligonucleotide (2142/2116)
that contained the Sp1 binding. The unlabeled oligonucleotide
(2102/273), containing the inverted Y-box, slightly decreased
the complex formation in a manner similar to that observed in
the experiment with the 299/241 probe (Fig. 4B, lane 4). To
determine the SREBP-1 binding sites, a gel mobility shift assay
was performed with mutant probes generated by PCR using
the same 32P-labeled sense primer (2142/2123). SREBP-1a
binding to m5 and m7 mutants was slightly decreased (Fig. 4C,
lanes 2 and 4). Introducing a double mutation (m517) nearly
abolished the SREBP-1a binding (Fig. 4C, lane 5), and the
shifted bands were completely abolished by triple mutations
(m41517) (data not shown). However, the mutation outside
the potential protein binding sites (m6) did not affect
SREBP-1a binding. Mutant m5, which has mutations 3 base
pairs away from CCAAT, did not affect NF-Y binding (data not
shown).
These gel retardation results show that NF-Y binds to the
inverted Y-box and that SREBP-1a binds to four regions, des-
ignated as regions A, B, C, and the inverted Y-box (Figs. 3A and
4A).
DNA Binding Domains of SREBPs Determine Their Poten-
cies on Transactivating the ACL Promoter—Although both
SREBP-1a and SREBP-2 have almost the same potencies to
activate the transcription of p5xSRE-tk, which contains five
copies of LDLR-SRE1 at the upstream of herpes simplex thy-
midine kinase promoter, SREBP-2 was a much less effective
activator than SREBP-1a for the ACL promoter (Fig. 5A).
Among the several possibilities that may explain the different
potencies, we first compared the binding affinities of SREBP-1a
and -2 with the ACL promoter SREs. Although SREBP-1a
showed no difference in binding to the LDLR-SRE1 and ACL
SREs, SREBP-2 bound to the ACL SREs much less efficiently
than to the LDLR-SRE1 (Fig. 5B). Therefore, the different
affinities of SREBPs to multiple SREs in ACL promoter might
explain the differences in their transactivation activities. How-
ever, it is still possible that the amino-terminal activation
domains of these factors might have different compatibilities to
the ACL promoter. To rule out this possibility, we constructed
two kinds of plasmids, p2A-1aD and p1aA-2D expressing chi-
meric SREBPs, of which the sequences for the amino-terminal
activation domain (amino acids 1–70) were exchanged as illus-
trated in Fig. 5C. The p2A-1aD could induce the ACL promoter
as efficiently as pCSA10, whereas p1aA-2D induced it to a
lesser extent, similar to pCS2 (Fig. 5D). This finding suggests
that the potencies of SREBPs in transactivating the ACL pro-
moter depend on the carboxyl-terminal portion of SREBPs but
not the amino-terminal activation domains and that the bind-
ing affinity of SREBPs to the promoter elements is an impor-
tant factor in determining the potency of transactivation.
The Functional Roles of SREBP-binding Elements and the
Inverted Y-box—To evaluate the functional significance of the
SREBP binding elements and the inverted Y-box in the ACL
promoter, a transient transfection experiment was performed.
FIG. 3. SREBPs and NF-Y bind to the proximal region of the ACL promoter. The sequences of wild type and mutant probes (nucleotides
299 to 241) utilized for the gel retardation assay are shown in A. The inverted Y-box (Inv. Y-box), SRE1, and Sp1 binding sites are underlined.
The mutated sequences are presented on the top of the strand at the respective positions. Mutants are named m1 to m4 and mSp1. Gel mobility
shift assays and competition assays shown in B were performed with the 32P-labeled wild type probe and recombinant SREBP-1a (1 mg). Unlabeled
oligonucleotides LDLR-SRE1, 2102/273 of the ACL promoter, the conserved NF-Y-binding sequence, and 267/241 of the ACL promoter were
added as competitors at 100-fold molar excess where indicated. The shifted DNA-protein complexes are indicated. C shows the gel mobility shift
assays using wild type probe (wt, lanes 1 and 5) or indicated mutant probes (lanes 2–4 and 6–8) and recombinant SREBP-1a. D shows the gel
mobility shift assays and supershift assays for NF-Y binding. The wild type probe (WT) and the nuclear extracts (7.5 mg) prepared from rat liver
were incubated in the absence or the presence of recombinant SREBP-1a (lanes 1 and 3). Anti-NF-YB (0.2 mg) was added where indicated (lanes
2 and 4). The shifted bands produced by DNA-protein complexes are indicated. The same assays were done with the inverted Y-box mutant m4
(lanes 5–8).


































The mutant clones, basically produced from pACL114, were
transiently transfected into Alexander cells, and their respon-
siveness to SREBP-1a was tested (Fig. 6). The constructs have
mutations that prevented the binding of SREBP-1a and/or
NF-Y in the gel mobility shift assays (Fig. 3, 4). Any single
mutation did not completely abolish the responsiveness of
pACL114 to SREBPs. Mutation at conserved SRE1 in region C
(m2) and at nucleotides in region B immediately upstream of
the inverted Y-box (m5) significantly decreased activation by
SREBPs without changing the basal transcription activity.
However, the m7 mutation did not affect the activation, even
though it also prevented the SREBP1a binding in gel mobility
shift assay. As region A exists at the vector-promoter junction
in pACL114, we could not exclude the possibility that the
neighboring vector sequences altered the binding affinity to
SREBP-1a and thereby made this site nonfunctional. The dou-
ble mutations at regions B and C (m215) completely abolished
the responsiveness of the ACL promoter to SREBP-1a without
a decrease in basal activity. The mutation at the inverted Y-box
(m4) significantly decreased the basal promoter activity as well
as the responsiveness to SREBP-1a. The double mutations at
region C and the inverted Y-box (m214) decreased the basal
promoter activity to a level similar to that of m4 and decreased
stimulation of the ACL promoter by SREBP-1a. The mutations
at the most proximal Sp1 binding site (mSp1) did not affect the
responsiveness of SREBP-1a. Because both SREBP1a and
NF-Y can bind to the inverted Y-box of the ACL promoter, we
needed to determine which was the responsible factor for the
decrease of responsiveness to SREBP-1a shown in the con-
structs containing the mutations at the inverted Y-box (m4). By
using the dominant negative mutant of NF-Y, pmYA, which
encodes the mutated A subunit of NF-Y lacking an ability to
FIG. 4. SREBP-1a binds to the upstream region containing the
inverted Y-box of the ACL promoter. A shows the sequence of
upstream probe (2142 to 280) used in the gel mobility shift assays. The
Sp1 binding site, SRE3, and the inverted Y-box (Inv. Y-box) are under-
lined. The mutated sequences are shown on the top of the strand at the
respective positions and are designated as m4, m5, m6, and m7. B
shows the gel mobility shift assays performed with 32P-labeled wild type
probes and recombinant SREBP-1a (1 mg). Unlabeled oligonucleotides
LDLR-SRE1, 2102/273 of the ACL promoter, the conserved NF-Y-
binding sequence, and 267/241 of the ACL promoter were added as
competitors at 100-fold molar excess where indicated. C shows the gel
mobility shift assays performed with wild type probe (wt) or indicated
mutant probes and recombinant SREBP-1a.
FIG. 5. Comparison of binding affinities between SREBP-1a
and SREBP-2 to the ACL promoter and activities of chimeric
SREBPs. The transient transfection assay shown in A was done by
introducing pACL114 or p5xSRE1-tk (0.5 mg) together with 40 ng of
expression plasmid. The fold increase was shown as the ratio of the
luciferase activities in the presence of expression plasmid to those in the
absence of expression plasmid. The gel mobility shift assay shown in B
was done with 32P-labeled LDLR-SRE1, ACL promoter fragments
2142/280, and 299/241. The probes were incubated with the indicated
amount of purified human SREBP-1a or SREBP-2 protein. Two chi-
meric SREBP expression plasmids, p2A-1aD and p1aA-2D, were gen-
erated by exchanging the coding sequences for amino acids 1–70 be-
tween SREBP-1a and -2, as illustrated in C. The ACL promoter-
luciferase construct, pACL114 (0.5 mg), was transfected together with
40 ng of the expression plasmids. Two days after transfection, cells were
harvested, and the luciferase activities were measured (D). The results
were expressed as the normalized luciferase activity/mg of protein in the
cell extracts. Values represent the mean 6 S.E. obtained from three
independent experiments performed in triplicate.
FIG. 6. The mutations of binding sites of SREBP-1a and NF-Y
in the ACL promoter attenuate the SREBP-1a-driven transacti-
vation of the ACL promoter-luciferase construct. The wild type
and mutant pACL114 constructs were illustrated schematically on the
left side of the graph. The mutant sequences are shown in Fig. 3 and 4.
Triplicate dishes of Alexander cells were transfected with 0.4 mg of
pACL114 and 0.2 mg of pCMV-b-galactosidase plasmid, together with
10 ng (gray bars) or 100 ng (black bars) of pCSA10 or pcDNA3 (white
bars). The total amount of transfected plasmids was adjusted to 0.8 mg
by adding pcDNA3. Two days after transfection, cells were harvested,
and the luciferase activities were assayed. Values represent the mean 6
S.E. from three independent experiments.


































bind to NF-Y consensus sequence (26), we could exclude the
NF-Y binding effect. When pmYA was added, the stimulation of
the ACL promoter activity by SREBP-1a and -2 was effectively
suppressed almost to the basal level (Fig. 7A). However,
SREBP-1a-induced activation of p5xSRE-tk was not changed
by adding pmYA. We could obtain the same result when the
construct containing mutations at the inverted Y-box (m4) was
used (data not shown). These results suggested that NF-Y
binding to the inverted Y-box is required for the effective trans-
activation of the ACL promoter by SREBPs.
DISCUSSION
SREBPs are known as a family of transcription factors that
regulate the genes involved in fatty acid and cholesterol syn-
thesis. It has been suggested that SREBP-1 and SREBP-2 have
different effects on target genes, that is, SREBP-1 preferen-
tially activates genes involved in fatty acid synthesis and
SREBP-2 activates genes involved in cholesterol synthesis. Re-
cent reports have suggested that SREBPs stimulates the ex-
pression of ACL gene and that SREBP-1a would be a more
specific factor. Shimomura et al. (30) reported that the level of
mRNA for ACL was elevated by 3- to 4-fold in transgenic mice
overexpressing the mature form of SREBP-1a or -1c and by
1.5-fold in transgenic mice overexpressing SREBP-2. In this
study, we demonstrate that the rat ACL promoter is highly
activated by the direct interaction of SREBPs with multiple
SREs on the ACL promoter, and that SREBP-1a is more effec-
tive activator than SREBP-2. In addition, we show that the
binding affinities of these SREBPs to ACL SREs determine
their potency in this promoter, supporting previous reports
that SREBPs have preferential target genes.
In the ACL promoter, the region between nucleotides 2114
and 260 was the major determinant for the activation by
SREBPs. The recombinant SREBP-1a strongly bound to three
regions, A, B, and C, in the proximal promoter of the ACL gene.
The SRE in region C (GTGAGCTGA) bears sequences homolo-
gous to SRE1, which has been found in many target genes of
SREBPs. As expected, mutations at region C significantly re-
duced the responsiveness to SREBPs without decreasing basal
activity of ACL promoter. The SRE in region B, the upstream
region of the inverted Y-box, showed a novel sequence (59-
AACGCGTGTG-39; 2104 to 295) differing from known consen-
sus SREs. The mutation at region B prevented the binding of
SREBP-1a (Fig. 4C) without changing NF-Y binding (data not
shown) and also decreased the stimulation of ACL promoter by
SREBP-1a (Fig. 6). Region A has sequences highly homologous
to SRE3, which was reported in glycerol 3-phosphate acyltrans-
ferase promoter. However, mutations in region A (m7) did not
alter the responsiveness to SREBPs, even though SREBP-1a
showed strong affinity to this region and its binding was sig-
nificantly reduced to the mutant probe (m7). The fact that
mutations at both SREs in region B and C resulted in complete
loss of responsiveness of the ACL promoter to SREBP-1a sug-
gested that these two SREs play important roles in SREBP-
mediated regulation.
The importance of the Sp1 binding sites for the action of
SREBPs has been reported in many promoters, such as LDL
receptor (31), acetyl-CoA carboxylase (22), and fatty acid syn-
thase promoter (32). But in the case of ACL, although the
deletion of five upstream Sp1 binding sites decreased the basal
activity of the ACL promoter, it did not alter the effect of
SREBPs activating the ACL promoter (Fig. 1). Also, the muta-
tion of the most proximal Sp1 binding site downstream of
region C did not affect the activation by SREBPs (Fig. 6). On
the other hand, the responsiveness to SREBPs was markedly
reduced when the binding of NF-Y was disturbed by the mu-
tation at the inverted Y-box or by the overexpression of the
dominant negative form of NF-YA (Figs. 6 and 7). These results
indicate that the regulation of the ACL promoter by SREBPs
requires the neighboring binding of NF-Y, as was observed in
farnesyl-pyrophosphate synthase, squalene synthase, hy-
droxymethylglutary-CoA synthase, glycerol-3-phosphate acyl-
transferase, and SREBP-2 genes (9, 10, 12, 25, 33).
The ACL promoter activation by SREBP-1a and 22 were
quite different. The amino-terminal 60 amino acid region of
SREBP-1a is known to be an activation domain that interacts
with multiprotein complex including CREB-binding protein
(34, 35). SREBP-1c, which is derived from the same gene as
SREBP-1a by using different transcription start site, is known
as a weak activator because of its short amino-terminal region
(36). However, the different potencies of SREBP-1a and -2 for
the ACL promoter activation were not originated from their
differences in activation domains. Instead, SREBP-2 showed
much less affinity to SREs in the ACL promoter than SREBP-
1a, and the chimeric SREBP, which has the SREBP-2 activa-
tion domain followed by remaining the carboxyl-terminal re-
gion of SREBP-1a, could activate the ACL promoter as
efficiently as SREBP-1a itself. This finding implies that
SREBPs can activate preferential target genes through their
different affinities to SREs in the promoters. The mechanism
by which SREBPs activate their preferential target genes has
not been studied thus far. Therefore, it will be necessary to
evaluate promoter selection by studying the binding affinity of
SREBP isoforms in other promoters too.
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FIG. 7. The stimulation of ACL promoter-luciferase construct
by SREBPs is dependent on NF-Y. The indicated amounts of
pCSA10 or pCS2 along with 0.4 mg of pACL114 and 0.2 mg of pCMV-
b-galactosidase plasmid were transfected into Alexander cells (A). Plas-
mid pcDNA3 (0.4 mg) or pmYA29 (0.4 mg) encoding a dominant negative
form of NF-YA was cotransfected as indicated. The plasmid p5xSRE-tk
(0.4 mg) was transfected with 40 ng of pCSA10 and 0.4 mg of pmYA as
indicated (B). The plasmid pUC9 was used to make the total amount of
transfected DNA equal. Two days after transfection, luciferase activi-
ties were measured. Normalized luciferase activities expressed as the
mean 6 S.E. from three independent experiments are shown.
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